Session » SLE – Treatment Poster II

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

Abstract Number: 1822

Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy

Abstract Number: 1823

Mycophenolate Mofetil for Systemic Lupus Erythematosus: Our 20-year Experience

Abstract Number: 1824

Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358

Abstract Number: 1825

Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases

Abstract Number: 1826

Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 2-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study

Abstract Number: 1827

Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials

Abstract Number: 1828

Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials

Abstract Number: 1829

Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period

Abstract Number: 1830

Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor

Abstract Number: 1831

Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus

Abstract Number: 1832

Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population

Abstract Number: 1833

Hydroxychloroquine and Vitamin D Both Reduce Proteinuria in SLE

Abstract Number: 1834

Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus

Abstract Number: 1835

Evaluation of Low Dose Glucocorticoid Effects on Infection Occurrence in Systemic Lupus Erythematosus Patients

Abstract Number: 1836

Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis

Abstract Number: 1837

Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort

Abstract Number: 1838

Aerobic Exercise Improves Fatigue and Quality of Life in Women with Systemic Lupus Erythematosus (Preliminary Analysis)

Abstract Number: 1839

Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE

Abstract Number: 1840

A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment

Abstract Number: 1841

Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus

Abstract Number: 1842

Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial

Abstract Number: 1843

Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids

Abstract Number: 1844

Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients

Abstract Number: 1845

Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study

Abstract Number: 1846

Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia

Abstract Number: 1847

Delayed and Immediate Release Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.